Tricida, Inc. TCDA
Set alert
0.11 0.00 0.00%
At close · Jan 23
0.0925 Day range 0.116
52-week range unavailable
- Open
- 0.1156
- Prev close
- 0.108
- Mkt cap
- 6.27M
- Vol
- 31.13M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0925
- High
- 0.116
- Forward P/E
- -0.09
- Beta
- 0.21
- Short ratio
- 1.53
- Inst. own
- 64.72%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 14, 2022
- 50-d avg
- 0.169858
- 200-d avg
- 6.86
- 1y target
- 20.00
Key statistics
- Market cap
- 6.27M
- Enterprise value
- 134.74M
- Trailing P/E
- 0.00
- Forward P/E
- -0.09
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -2.88
- Beta
- 0.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -65.87M
- Total cash
- 80.22M
- Total debt
- 208.00M
- Return on equity
- 0.00%
- Shares outstanding
- 58.03M
- Short % of float
- 31.33%
- 50-day average
- 0.169858
- 200-day average
- 6.86
Analyst view
Consensus: hold
Hold
Price target (mean) 20.00
Ratings (0m) 3 1 buy · 2 hold · 0 sell
- Strong buy0
- Buy1
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 14, 2022
Expected Nov 14, 2022. Consensus EPS estimate -0.54.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2022 | Sep 1, 2022 | -0.54 | — | — | — |
| Aug 8, 2022 | Jun 1, 2022 | -0.52 | — | — | — |
| May 10, 2022 | Mar 1, 2022 | -0.64 | — | — | — |
| Mar 29, 2022 | Dec 1, 2021 | -0.71 | — | — | — |
| Nov 8, 2021 | Sep 1, 2021 | -0.70 | — | — | — |
| Aug 9, 2021 | Jun 1, 2021 | -0.72 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 25, 2022 | JP Morgan | down | Neutral | Underweight |
| Oct 25, 2022 | Needham | down | Buy | Hold |
| Oct 24, 2022 | Cowen & Co. | down | Outperform | Market Perform |
| May 24, 2022 | Goldman Sachs | main | — | Buy |
| May 11, 2022 | Goldman Sachs | main | — | Buy |
| Apr 13, 2022 | Goldman Sachs | init | — | Buy |
About Tricida, Inc.
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California. On January 11, 2023, Tricida, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tricida.com
News
- SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tricida, Inc.
- Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
- Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- Tricida files for Chapter 11 bankruptcy protection as it searches for a buyer
- Stocks That Hit 52-Week Lows On Thursday
- Top 10 most-shorted stocks as of November 2022
- What Penny Stocks Industries Are Popular Right Now?
- Tricida Announces Third Quarter 2022 Financial Results
- Tricida Announces Third Quarter 2022 Financial Results
- What to Look For in Penny Stocks Under $1, 3 Tips
Your note
Sign in to keep a note on TCDA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALPERN ROBERT J | Director | Sale | Nov 22, 2022 | 0 |
| BONITA DAVID P | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 24, 2022 | 0 |
| COUFAL SANDRA I | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 19, 2021 | 6,527,360 |
| FALBERG KATHRYN E. | Director | Stock Award(Grant) | Jun 9, 2021 | 59,163 |
| ISERN BRIAN M | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 12, 2022 | 0 |
| KLAERNER GERRIT | Chief Executive Officer | Sale | Dec 7, 2021 | 395,480 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 18.47% | 10,280,947 | 1.11M | Sep 29, 2022 |
| VR Adviser, LLC | 16.26% | 9,050,064 | 977.41K | Sep 29, 2022 |
| Blackrock Inc. | 6.64% | 3,698,400 | 399.43K | Sep 29, 2022 |
| Frazier Life Sciences Management, L.P. | 4.58% | 2,549,671 | 275.36K | Sep 29, 2022 |
| Commodore Capital, LP | 3.55% | 1,975,403 | 213.34K | Sep 29, 2022 |
| Vanguard Group, Inc. (The) | 2.99% | 1,661,860 | 179.48K | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.83% | 1,021,422 | 110.31K | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 0.59% | 330,277 | 35.67K | Sep 29, 2022 |
| iShares Russell 2000 Value ETF | 0.51% | 281,986 | 30.45K | Dec 30, 2022 |
| Fidelity Small Cap Index Fund | 0.47% | 261,685 | 28.26K | Oct 30, 2022 |
| iShares Russell 3000 ETF | 0.42% | 232,156 | 25.07K | Dec 30, 2022 |
| Goldman Sachs Small Cap Value Insights Fund | 0.26% | 143,676 | 15.52K | Oct 30, 2022 |